Search the Newsreel

Compass Therapeutics (CMPX) Short Interest & Short Float | Updated Aug 2026

As of July 31, 2026, Compass Therapeutics (CMPX) had a short interest of 39.87 million shares, representing 27.23% of its public float, marking a 1.47% increase from the prior report. The short interest ratio is 17.6 days to cover, indicating a significant amount of …

HC Wainwright Issues Pessimistic Estimate for CMPX Earnings

We're Not Very Worried About Compass Therapeutics' (NASDAQ:CMPX) Cash Burn Rate

Compass Therapeutics (NASDAQ:CMPX) is not causing concern despite its cash burn rate. The company has a cash runway of 3.4 years, and analysts predict it will reach cash flow breakeven before exhausting its funds. Although cash burn increased by 18% last year, its market …

Compass Therapeutics (NASDAQ:CMPX) Rating Lowered to Strong Sell at Wall Street Zen

Wall Street Zen has downgraded Compass Therapeutics (NASDAQ:CMPX) from a "sell" to a "strong sell" rating, despite a broader analyst consensus of "Moderate Buy." The company reported a quarterly loss of $0.13 per share, missing analyst expectations, and its shares opened near their 52-week …

Compass Therapeutics (NASDAQ:CMPX) Posts Earnings Results, Misses Expectations By $0.02 EPS

Compass Therapeutics (NASDAQ:CMPX) reported a quarterly loss of $0.13 per share, missing analyst expectations by $0.02. Despite the earnings miss, the stock rose to $2.15 in Friday trading, though it remains significantly below its 12-month high. Analysts maintain a "Moderate Buy" rating with an …

Compass Therapeutics Inc. (CMPX) Stock News Today

This article provides current stock news for Compass Therapeutics Inc. (CMPX), including its recent stock performance, market capitalization, and a note about upcoming earnings. As of the close on August 7th, CMPX stock was up 8.04% at $2.150. The content highlights the company's financial …

Form 8K Compass Therapeutics, Inc. For: 6 August By Investing.com

The article reports on a Form 8K filing by Compass Therapeutics, Inc. for August 6th. The publication, from Investing.com, indicates the filing is publicly available for review. This brief announcement is situated within a broader financial news platform.

Compass Therapeutics Inc. (CMPX) Earnings Forecast: Future EPS & Revenue Growth Estimates

Compass Therapeutics, Inc. Stock 12‑Month Price Target Raised to $8.67, Implies 359% Upside

Compass Therapeutics, Inc. (CMPX) has seen its average 12-month stock price target raised to $8.67 from $8.50 by 12 analysts, with forecasts ranging from $4 to $24 per share. This new target suggests a potential upside of approximately 359% based on the Aug. 5 …

Compass Therapeutics, Inc. 2026: Revenue ($25.25M), Net income ($25.15M), EPS ($0.13) — 10-Q Summary

Compass Therapeutics, Inc. reported its 2026 quarterly results, showing increased comprehensive and net losses compared to the previous year, driven by advancements in multiple clinical programs and expanded pre-commercialization spending. Despite the losses, the company highlighted positive clinical milestones, pipeline progress with four advancing …

Compass Therapeutics (NASDAQ: CMPX) details Q2 loss and BTC trial gains

Compass Therapeutics (

Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update

Compass Therapeutics reported its second-quarter 2026 financial results, highlighting a cash position of $180 million expected to fund operations into 2028. The company is advancing several clinical-stage oncology programs, with key updates including anticipated FDA feedback on tovecimig data, ongoing enrollment for CTX-8371 and …

Compass Therapeutics (CMPX) Earnings Date and Reports 2026

Compass Therapeutics Inc. (CMPX) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Compass Therapeutics Inc. (CMPX), detailing its price momentum, support and resistance levels, and various technical indicators. The stock currently has a price momentum score of 4.33, trading between resistance at $2.28 and support at $1.77. While some …

CMPX|Compass Therapeutics Inc.|Price:1.940|

This article provides a detailed overview of Compass Therapeutics Inc. (CMPX), including its current market trends, real-time quotes, and related analysis. It highlights the company's healthy fundamentals, significant growth potential, and "Buy" ratings from analysts, despite recent stock market underperformance. The company is a …

CMPX|Compass Therapeutics Inc.|Price:2.092|Chg%:+0.022

This article provides a detailed company profile of Compass Therapeutics, Inc., a clinical-stage oncology biopharmaceutical company. It outlines their proprietary antibody-based therapeutic pipeline, including lead candidate tovecimig and other programs like CTX-471 and CTX-8371, which target various critical biological pathways for anti-tumor responses. The …

CMPX|Compass Therapeutics Inc.|Price:2.080|

This article provides a comprehensive stock analysis of Compass Therapeutics Inc. (CMPX), highlighting its healthy fundamentals, significant growth potential, and relatively fair valuation within the Biotechnology & Medical Research industry. It details the company's product pipeline including tovecimig, CTX-471, and CTX-8371, and notes high …

Compass Therapeutics Inc. (CMPX) Financial Health: Profitability & Balance Sheet Analysis

This article analyzes the financial health of Compass Therapeutics Inc. (CMPX), assigning it a current financial score of 6.37, which ranks 259 out of 386 in the Biotechnology & Medical Research industry. The company's financial status is described as robust, but its operating efficiency …

TradingKey

This article provides a detailed quarterly and annual income statement for Compass Therapeutics Inc. (CMPX). It includes financial data such as total revenue, operating expenses, R&D expenses, operating profit, net non-operating interest income, income before tax, income after tax, net income, and earnings per …

Compass Therapeutics, Inc. Revenue Breakdown – NASDAQ:CMPX

This article provides a revenue breakdown for Compass Therapeutics, Inc. (NASDAQ: CMPX) on the TradingView platform. It highlights that the market was closed with no trades at the time of publication and offers financial data, news, community interaction, and technical analysis tools for the …

Compass Therapeutics Inc. (CMPX) Institutional Confidence

Compass Therapeutics Inc. (CMPX) has an institutional shareholding score of 10.00, placing it first in the Biotechnology & Medical Research industry. Institutional investors hold 90.26% of outstanding shares, a 28.41% increase quarter-over-quarter. The largest institutional shareholder is Bill Nygren | OAKMX, although their holdings …

Monashee Investment Management LLC Sells 741,135 Shares of Compass Therapeutics, Inc. $CMPX

Compass Therapeutics (CMPX) Jefferies Global Healthcare Conference 2026 Summary

This article summarizes Compass Therapeutics' presentation at the Jefferies Global Healthcare Conference 2026, highlighting key clinical results and upcoming regulatory milestones. Their lead asset, tovecimig, showed significant efficacy in biliary tract cancer, with an FDA meeting scheduled for early to mid-August and a rolling …

Compass Therapeutics to present Phase 2/3 tovecimig trial results at ESMO 2026 in advanced biliary tract cancer

Compass Therapeutics will present Phase 2/3 clinical trial results for its bispecific antibody, tovecimig, combined with paclitaxel, at the ESMO Congress 2026. The presentation will focus on data from the COMPANION-002 trial in advanced biliary tract cancer, led by Dr. Nilofer Azad. This event …

Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026

Compass Therapeutics announced that its abstract featuring data from the COMPANION-002 clinical trial of tovecimig, a bispecific antibody, has been accepted for an oral presentation at the ESMO Congress 2026. The presentation will detail results of the randomized Phase 2/3 trial evaluating tovecimig in …

CMPX Forecast — Price Target — Prediction for 2027

Compass Therapeutics, Inc. 1Q 2026: Revenue ($18.76M), EPS ($0.1) — 10-Q Summary

CMPX Stock Plunges As Volatility Grips Compass Therapeutics

Compass Therapeutics, Inc.'s (NASDAQ:CMPX) Path To Profitability

CMPX Rises As Compass Therapeutics Sets Key Cancer Data Webcast

Wall Street Analysts See an 113.73% Upside in Compass Therapeutics, Inc. (CMPX): Can the Stock Really Move This High?

Compass Therapeutics Inc (CMPX) Earnings, Actual EPS, EPS Estimates & Results

What is the current Price Target and Forecast for Compass Therapeutics, Inc. (CMPX)